No abstract available.
Hemorrhage* ; Pregnancy* ; Round Ligament of Uterus*

No abstract available.
Chlamydia* ; Fluorescent Antibody Technique, Indirect*

No abstract available.
Angiomyoma ; Ear

No abstract available.
Drug Therapy* ; Methotrexate* ; Uterine Cervical Neoplasms*

No abstract available
Apoptosis ; Humans* ; Thymocytes*

No abstract available.
Broad Ligament* ; Female ; Hemorrhage* ; Pregnancy*

Chronic pelvic pain is a common and significant disorder of women. It is estimated to have a prevalence of 3.8% in women. The etiology of chronic pelvic pain in women is poorly understood. Although a specific diagnosis is not found in the majority of cases, some common diagnoses include endometriosis, adhesions, irritable bowel syndrome, and interstitial cystitis. The initial history and physical examination can narrow the diagnostic possibilities, guide any subsequent evaluation, and rule out malignancy or significant systemic disease. If the initial evaluation does not reveal a specific diagnosis, a limited laboratory and ultrasound evaluation can clarify the diagnosis, as well as rule out serious disease and reassure the patient. Laboratory and imaging studies should be selectively utilized, as should laparoscopy. Conscious laparoscopic pain mapping has been proposed as a way to improve information derived from laparoscopic evaluations.
Cystitis, Interstitial ; Endometriosis ; Female ; Humans ; Irritable Bowel Syndrome ; Laparoscopy ; Pelvic Pain ; Physical Examination ; Prevalence

The study performed a systematic review of screening for preeclampsia with the combination of vascular parameters and maternal serum markers in the first and early second trimester. We identified eligible studies through a search of Medline, and, for each included study, we focused on the relationship between the maternal serum markers and preeclampsia. In the selected literature, a combination of maternal serum markers was analyzed, also. Several tests suggested moderate or convincing prediction of early preeclampsia, but screening for late preeclampsia was poor. Literatures for serum markers were selected. Each serum marker was identified independently, and where relevant, a combination of these markers was analyzed. Encouraging results for the first trimester screening were observed when it was combined with other markers. Even in the first trimester of pregnancy, we can present the reliable results for the prediction of early preeclampsia. Detection rate for combination markers may yield higher detection rate and be promising to identify patients at high risk of developing preeclampsia.
Biomarkers ; Blood Pressure ; Female ; Humans ; Mass Screening ; Pre-Eclampsia ; Pregnancy ; Pregnancy Trimester, First ; Pregnancy Trimester, Second

OBJECTIVE: To evaluate the effects of low dose estrogen replacement therapy on the lipid profile in the postmenopausal women. METHODS: This prospective randomized clinical trial examined the effects of low dose conjugated equine estrogen on lipid profile in 140 postmenopausal women. Treatment included 0.625 mg conjugated equine estrogen (group I, n=75), or 0.31mg conjugated equine estrogen (group II, n=55) for 12 months. Lipid profile were performed at months 6 and 12 months. RESULTS: HDL cholesterol increased significantly during the treatment in Group I and Group II. LDL cholesterol decreased significantly during the treatment in Group I and Group II. Total cholesterol in Group I and Group II decreased during treatment, but not significantly. As triglyceride increased slightly during the treatment in Group I and Group II but not significantly. CONCLUSION: The low dose conjugated equine estrogen is also positive changes on lipid profile.
Cholesterol ; Cholesterol, HDL ; Cholesterol, LDL ; Estrogen Replacement Therapy* ; Estrogens* ; Female ; Humans ; Prospective Studies ; Triglycerides

OBJECTIVE: To evaluate the effects of low dose estrogen replacement therapy on the lipid profile in the postmenopausal women. METHODS: This prospective randomized clinical trial examined the effects of low dose conjugated equine estrogen on lipid profile in 140 postmenopausal women. Treatment included 0.625 mg conjugated equine estrogen (group I, n=75), or 0.31mg conjugated equine estrogen (group II, n=55) for 12 months. Lipid profile were performed at months 6 and 12 months. RESULTS: HDL cholesterol increased significantly during the treatment in Group I and Group II. LDL cholesterol decreased significantly during the treatment in Group I and Group II. Total cholesterol in Group I and Group II decreased during treatment, but not significantly. As triglyceride increased slightly during the treatment in Group I and Group II but not significantly. CONCLUSION: The low dose conjugated equine estrogen is also positive changes on lipid profile.
Cholesterol ; Cholesterol, HDL ; Cholesterol, LDL ; Estrogen Replacement Therapy* ; Estrogens* ; Female ; Humans ; Prospective Studies ; Triglycerides